Immunology

CV Sciences, Inc. Receives NutraIngredients-USA 2021 Product of the Year: Immune Support Award

Drugs, Medical specialties, Health care, Immunology, Anticonvulsants, Cannabidiol, Cannabinoids, Resorcinols, Hemp, Immunity
Tuesday, July 27, 2021 - 1:00pm

SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the Company, CV Sciences, our, us or we), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, announced today that it received NutraIngredients-USA s 2021 Product of the Year: Immune Support Award for its CV Defense product.

Key Points: 
  • SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the Company, CV Sciences, our, us or we), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, announced today that it received NutraIngredients-USA s 2021 Product of the Year: Immune Support Award for its CV Defense product.
  • The active ingredients in CV Defense are backed by hundreds of scientific studies for daily support of barrier immunity, innate immunity, and adaptive immunity.
  • CV Defense by CV Sciences stood out in a crowded category, said Stephen Daniells, PhD, Editor-in-Chief of NutraIngredients-USA.
  • This award also validates our strategic decision to expand our product portfolio beyond the hemp-derived CBD category that we pioneered.

Biodesix to Report Second Quarter 2021 Financial Results on August 10, 2021

Biotechnology, Health, Clinical trials, Other Health, Medical specialties, Branches of biology, Clinical medicine, Immunology, Antibodies, Chemical pathology, Communication, Forward-looking statement, Anti-SSA/Ro autoantibodies, Vaccine
Tuesday, July 27, 2021 - 11:00am

Biodesix is the first company to offer seven non-invasive tests for patients with diseases of the lung, including three proteomic tests.

Key Points: 
  • Biodesix is the first company to offer seven non-invasive tests for patients with diseases of the lung, including three proteomic tests.
  • The antibody tests can detect antibodies that are generated both from infection by the virus and from the vaccines.
  • Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors.
  • Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law.

Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets

Medical specialties, Clinical medicine, Immunology, Medicine, Biotechnology, Monoclonal antibodies, Antibody-drug conjugate, Immune system, Antibody
Tuesday, July 27, 2021 - 8:00am

Under the terms of the platform access agreement, Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs).

Key Points: 
  • Under the terms of the platform access agreement, Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs).
  • The antibodies generated by Glycotope are designed to deliver very high tumor selectivity.
  • Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies.
  • Glycotope has to date discovered in excess of 130 GlycoTargets with antibodies against several of these targets currently under development.

Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets

Medical specialties, Clinical medicine, Immunology, Medicine, Biotechnology, Monoclonal antibodies, Antibody-drug conjugate, Immune system, Antibody
Tuesday, July 27, 2021 - 8:00am

Under the terms of the platform access agreement, Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs).

Key Points: 
  • Under the terms of the platform access agreement, Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs).
  • The antibodies generated by Glycotope are designed to deliver very high tumor selectivity.
  • Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies.
  • Glycotope has to date discovered in excess of 130 GlycoTargets with antibodies against several of these targets currently under development.

Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets

Medical specialties, Clinical medicine, Immunology, Medicine, Biotechnology, Antineoplastic drugs, Antibody-drug conjugate, Immune system, Monoclonal antibody, Antibody
Tuesday, July 27, 2021 - 8:00am

Under the terms of the platform access agreement, Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs).

Key Points: 
  • Under the terms of the platform access agreement, Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs).
  • This agreement with Byondis highlights the potential of our GlycoTarget discovery and technology platform, said Henner Kollenberg, Managing Director of Glycotope.
  • Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies.
  • Glycotope has to date discovered in excess of 130 GlycoTargets with antibodies against several of these targets currently under development.

Agenus to Provide Corporate Update and Second Quarter 2021 Financial Report

Medical specialties, Agenus, Clinical medicine, Medicine, Cancer immunotherapy, Immunology, Vaccine, Immune response, Cancer
Monday, July 26, 2021 - 9:05pm

LEXINGTON, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will release its second quarter 2021 financial results before the market opens on Monday, August 9, 2021.

Key Points: 
  • LEXINGTON, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will release its second quarter 2021 financial results before the market opens on Monday, August 9, 2021.
  • Agenus executives will host a conference call and webcast at 8:30 a.m.
  • ET the same day to discuss the results and to provide a corporate update.
  • Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer.

Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery

Technology, Research, Genetics, Software, Biotechnology, Health, Pharmaceutical, Science, Oncology, Immunology, Antibody, Glycoproteins, Twist Bioscience, Emily Leproust, Biology, Life sciences
Monday, July 26, 2021 - 1:00pm

The collaborative research project resulted from a technology agreement between the companies to pursue novel antibody targets through Twists antibody discovery and optimization together with MOLCUREs AI technology.

Key Points: 
  • The collaborative research project resulted from a technology agreement between the companies to pursue novel antibody targets through Twists antibody discovery and optimization together with MOLCUREs AI technology.
  • Our expectations that this would reinforce our partners therapeutic antibody pipelines and further strengthen our AI driven molecule design service were confirmed in this project.
  • Twist Bioscience continues to innovate and incorporate the most advanced methods of antibody discovery and optimization into our processes, said Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • MOLCUREs AI approach complements our proprietary antibody discovery and optimization efforts, leveraging technology to refine our internal antibody pipeline.

NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1 Study of NT-I7 (efineptakin alfa) for the Treatment of Kaposi Sarcoma in Patients With or Without HIV Infection

Research, Other Health, General Health, Pharmaceutical, Oncology, Infectious diseases, Clinical trials, Science, Biotechnology, AIDS, FDA, Health, Other Science, Medical specialties, Branches of biology, Clinical medicine, HIV/AIDS, Immunology, Immune system, Sexually transmitted diseases and infections, Kaposi's sarcoma, Lymphocytopenia, HIV, CD4, T helper cell
Monday, July 26, 2021 - 12:00pm

Kaposi Sarcoma (KS) is an angioproliferative tumor associated with infection by Kaposi sarcoma-associated herpes virus (KSHV).

Key Points: 
  • Kaposi Sarcoma (KS) is an angioproliferative tumor associated with infection by Kaposi sarcoma-associated herpes virus (KSHV).
  • The identification of a viral etiology of KS helped explain the long-observed association between KS and immunosuppression, specifically CD4+ T cell lymphopenia, commonly seen with HIV infection.
  • In chronic uncontrolled HIV infection, physiologic doses of IL-7 are unable to prevent CD4+ lymphopenia.
  • Furthermore, lymphopenia-inducing insults that may occur in the treatment of KS with anti-neoplastic or radiation treatment could result in a prolonged CD4+ T cell depletion.

BlueRock Therapeutics Announces New Board Chair, New President and CEO

Companies, Industry economics), Aspirin, Bayer, IG Farben, Leverkusen, Economy of Germany
Monday, July 26, 2021 - 1:00pm

CAMBRIDGE, Mass., July 26, 2021 /PRNewswire/ -- BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of BayerAG, announcedtodaythat Emile Nuwaysir, Ph.D., current President and CEO, will transition to the position of BlueRock Board Chair, effective August 1, 2021.

Key Points: 
  • CAMBRIDGE, Mass., July 26, 2021 /PRNewswire/ -- BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of BayerAG, announcedtodaythat Emile Nuwaysir, Ph.D., current President and CEO, will transition to the position of BlueRock Board Chair, effective August 1, 2021.
  • Current Chief Scientific Officer Seth Ettenberg, Ph.D., will assume the role of President and CEO.
  • BlueRock will continue in its mission to create authentic cellular medicines to reverse devastating diseases and improve the human condition.
  • BlueRock also recently initiated a first-of-its-kind trial of pluripotent stem-cell derived dopaminergic neurons in patients with advanced Parkinson's disease.

Lee’s Pharmaceutical Announces First Patient Dosed With its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, as a First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer

Clinical medicine, Medicine, Medical specialties, Immunology, Immune system, Biotechnology, Clusters of differentiation, Cancer treatments, Monoclonal antibody, PD-L1, PD-1 and PD-L1 inhibitors, Atezolizumab
Friday, July 23, 2021 - 4:37pm

Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lees Pharm.

Key Points: 
  • Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lees Pharm.
  • Socazolimab is a fully human anti-PD-L1 monoclonal antibody identified by Sorrento using its proprietary G-MAB library platform.
  • COF received exclusive rights to develop and commercialize the antibody for Greater China, which includes Mainland China, Hong Kong, Macau, and Taiwan.
  • Forward-looking statements include statements regarding the potential efficacy and safety profile of a Socazolimab product candidate in patients with extensive-stage small-cell lung cancer.